US 11,911,462 B2
Nucleic acid vaccine against the SARS-CoV-2 coronavirus
Etienne Simon-Loriere, Paris (FR); Matthieu Prot, Paris (FR); and Xavier Montagutelli, Paris (FR)
Assigned to INSTITUT PASTEUR, Paris (FR)
Filed by INSTITUT PASTEUR, Paris (FR)
Filed on Jul. 12, 2023, as Appl. No. 18/351,065.
Application 18/351,065 is a continuation of application No. 17/819,187, filed on Aug. 11, 2022, granted, now 11,759,516.
Application 17/819,187 is a continuation of application No. PCT/EP2021/025053, filed on Feb. 12, 2021.
Claims priority of provisional application 62/976,148, filed on Feb. 13, 2020.
Claims priority of application No. 20305140 (EP), filed on Feb. 13, 2020.
Prior Publication US 2024/0000922 A1, Jan. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/63 (2006.01); A61K 39/215 (2006.01); C12P 19/34 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/215 (2013.01) [C12N 15/63 (2013.01); C12P 19/34 (2013.01); A61K 2039/51 (2013.01)] 13 Claims
 
1. An endotoxin-free preparation of a DNA plasmid construct encoding an mRNA encoding a SARS-CoV-2 virus Spike (S) protein antigen comprising a signal peptide comprising the amino acid sequence of SEQ ID NO:5, wherein said DNA construct comprises a sequence having at least 90% identity with the nucleotide sequence of SEQ ID NO:10, and wherein said DNA construct comprises a Kozak sequence comprising the sequence GCCACC in positions −6 to −1 relative to the ATG initiation codon of the S protein antigen.